- Home
- HOWL vs SLS Comparison
HOWL vs SLS Comparison
Compare HOWL & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- SLS
- Stock Information
- Founded
- HOWL 2017
- SLS 2012
- Country
- HOWL United States
- SLS United States
- Employees
- HOWL N/A
- SLS N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- SLS Health Care
- Exchange
- HOWL Nasdaq
- SLS Nasdaq
- Market Cap
- HOWL 87.4M
- SLS 75.3M
- IPO Year
- HOWL 2021
- SLS N/A
- Fundamental
- Price
- HOWL $1.79
- SLS $1.22
- Analyst Decision
- HOWL Strong Buy
- SLS Buy
- Analyst Count
- HOWL 2
- SLS 1
- Target Price
- HOWL $13.50
- SLS $3.00
- AVG Volume (30 Days)
- HOWL 656.6K
- SLS 814.5K
- Earning Date
- HOWL 11-07-2024
- SLS 11-13-2024
- Dividend Yield
- HOWL N/A
- SLS N/A
- EPS Growth
- HOWL N/A
- SLS N/A
- EPS
- HOWL N/A
- SLS N/A
- Revenue
- HOWL $3,386,000.00
- SLS N/A
- Revenue This Year
- HOWL N/A
- SLS N/A
- Revenue Next Year
- HOWL $191.98
- SLS N/A
- P/E Ratio
- HOWL N/A
- SLS N/A
- Revenue Growth
- HOWL N/A
- SLS N/A
- 52 Week Low
- HOWL $1.58
- SLS $0.50
- 52 Week High
- HOWL $8.19
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- HOWL 32.55
- SLS 47.94
- Support Level
- HOWL $1.58
- SLS $1.22
- Resistance Level
- HOWL $2.24
- SLS $1.39
- Average True Range (ATR)
- HOWL 0.16
- SLS 0.10
- MACD
- HOWL -0.09
- SLS 0.00
- Stochastic Oscillator
- HOWL 7.01
- SLS 32.00
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.